These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

429 related articles for article (PubMed ID: 20117339)

  • 1. Biological markers in inflammatory bowel disease: practical consideration for clinicians.
    Mendoza JL; Abreu MT
    Gastroenterol Clin Biol; 2009 Jun; 33 Suppl 3():S158-73. PubMed ID: 20117339
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices.
    Langhorst J; Elsenbruch S; Koelzer J; Rueffer A; Michalsen A; Dobos GJ
    Am J Gastroenterol; 2008 Jan; 103(1):162-9. PubMed ID: 17916108
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fecal markers: calprotectin and lactoferrin.
    Abraham BP; Kane S
    Gastroenterol Clin North Am; 2012 Jun; 41(2):483-95. PubMed ID: 22500530
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serologic markers in inflammatory bowel disease (IBD).
    Nakamura RM; Barry M
    MLO Med Lab Obs; 2001 Nov; 33(11):8-15; quiz 16-9. PubMed ID: 11721286
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Calprotectin: a fecal marker for diagnosis and follow-up in patients with chronic inflammatory bowel disease].
    van den Bergh FA; Kolkman JJ; Russel MG; Vlaskamp RT; Vermes I
    Ned Tijdschr Geneeskd; 2003 Nov; 147(48):2360-5. PubMed ID: 14677476
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serologic markers: impact on early diagnosis and disease stratification in inflammatory bowel disease.
    Arai R
    Postgrad Med; 2010 Jul; 122(4):177-85. PubMed ID: 20675980
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serologic testing with ANCA, ASCA, and anti-OmpC in children and young adults with Crohn's disease and ulcerative colitis: diagnostic value and correlation with disease phenotype.
    Zholudev A; Zurakowski D; Young W; Leichtner A; Bousvaros A
    Am J Gastroenterol; 2004 Nov; 99(11):2235-41. PubMed ID: 15555007
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New serologic markers for inflammatory bowel disease diagnosis.
    Dotan I
    Dig Dis; 2010; 28(3):418-23. PubMed ID: 20926866
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New serological markers for inflammatory bowel disease are associated with earlier age at onset, complicated disease behavior, risk for surgery, and NOD2/CARD15 genotype in a Hungarian IBD cohort.
    Papp M; Altorjay I; Dotan N; Palatka K; Foldi I; Tumpek J; Sipka S; Udvardy M; Dinya T; Lakatos L; Kovacs A; Molnar T; Tulassay Z; Miheller P; Norman GL; Szamosi T; Papp J; ; Lakatos PL
    Am J Gastroenterol; 2008 Mar; 103(3):665-81. PubMed ID: 18047543
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical utility of serological markers in inflammatory bowel disease.
    Mokrowiecka A; Daniel P; Słomka M; Majak P; Malecka-Panas E
    Hepatogastroenterology; 2009; 56(89):162-6. PubMed ID: 19453050
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Biomarkers in the diagnosis and therapy of inflammatory bowel diseases].
    Iijima H; Shinzaki S; Tsujii M; Takehara T
    Nihon Rinsho; 2012 May; 70(5):869-73. PubMed ID: 22620015
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic value of anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease.
    Peeters M; Joossens S; Vermeire S; Vlietinck R; Bossuyt X; Rutgeerts P
    Am J Gastroenterol; 2001 Mar; 96(3):730-4. PubMed ID: 11280542
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Relevance of serologic studies in inflammatory bowel diseases].
    Papp M; Altorjay I; Lakatos PL
    Orv Hetil; 2007 May; 148(19):887-96. PubMed ID: 17478404
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Accuracy of four fecal assays in the diagnosis of colitis.
    Schoepfer AM; Trummler M; Seeholzer P; Criblez DH; Seibold F
    Dis Colon Rectum; 2007 Oct; 50(10):1697-706. PubMed ID: 17762964
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serological markers in diagnosis of pediatric inflammatory bowel disease and as predictors for early tumor necrosis factor blocker therapy.
    Olbjørn C; Cvancarova Småstuen M; Thiis-Evensen E; Nakstad B; Vatn MH; Perminow G
    Scand J Gastroenterol; 2017 Apr; 52(4):414-419. PubMed ID: 27887202
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Update of fecal markers of inflammation in inflammatory bowel disease.
    Judd TA; Day AS; Lemberg DA; Turner D; Leach ST
    J Gastroenterol Hepatol; 2011 Oct; 26(10):1493-9. PubMed ID: 21777275
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Review of fecal biomarkers in inflammatory bowel disease.
    Sutherland AD; Gearry RB; Frizelle FA
    Dis Colon Rectum; 2008 Aug; 51(8):1283-91. PubMed ID: 18543035
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fecal leukocyte proteins in inflammatory bowel disease and irritable bowel syndrome.
    Silberer H; Küppers B; Mickisch O; Baniewicz W; Drescher M; Traber L; Kempf A; Schmidt-Gayk H
    Clin Lab; 2005; 51(3-4):117-26. PubMed ID: 15819166
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel anti-glycan antibodies related to inflammatory bowel disease diagnosis and phenotype.
    Seow CH; Stempak JM; Xu W; Lan H; Griffiths AM; Greenberg GR; Steinhart AH; Dotan N; Silverberg MS
    Am J Gastroenterol; 2009 Jun; 104(6):1426-34. PubMed ID: 19491856
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical utility of calprotectin and lactoferrin as markers of inflammation in patients with inflammatory bowel disease.
    Caccaro R; D'Incá R; Sturniolo GC
    Expert Rev Clin Immunol; 2010 Jul; 6(4):551-8. PubMed ID: 20594128
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.